TIANJIN DEV(00882): Tianjin Lisheng Pharmaceutical's net profit attributable to the parent company for the first three quarters was 371 million yuan, an increase of 119.05% year-on-year.

06:14 24/10/2025

Tianjin Development (00882) announced that its indirect non-wholly owned subsidiary, Tianjin Lisheng Pharmaceutical Co., Ltd.

TIANJIN DEV (00882) announced that its indirect non-wholly owned subsidiary, Tianjin Lisheng Pharmaceutical Co., Ltd. (Tianjin Lisheng Pharmaceutical), has achieved a total operating income of 1.007 billion yuan in the nine months ending September 30, 2025, a decrease of 1.61% compared to the same period last year. Net profit attributable to the owners of the parent company was 371 million yuan, an increase of 119.05% year-on-year, with basic earnings per share of 1.44 yuan.

HK Stock Market Move | AFFLUENT FDN (01757) resumed trading and rose nearly 20% after China Venture Capital Holdings acquired 75% of the shares and offered a cash offer at a discount of about 79.06%.

Guosheng Securities: Overall performance of thermal power in Q3 is on the rise, emphasizing on switching styles and focusing on power allocation.

HK Stock Market Move | CHINA LIT (00772) rose nearly 5% in early trading, the company launched four major initiatives to layout the comic ecology, actively promoting the commercialization of IP.

HK Stock Market Move | AFFLUENT FDN (01757) resumed trading and rose nearly 20% after China Venture Capital Holdings acquired 75% of the shares and offered a cash offer at a discount of about 79.06%.

Guosheng Securities: Overall performance of thermal power in Q3 is on the rise, emphasizing on switching styles and focusing on power allocation.

HK Stock Market Move | CHINA LIT (00772) rose nearly 5% in early trading, the company launched four major initiatives to layout the comic ecology, actively promoting the commercialization of IP.